for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fluidigm Corporation

FLDM.OQ

Latest Trade

5.59USD

Change

-0.21(-3.62%)

Volume

767,414

Today's Range

5.57

 - 

5.80

52 Week Range

5.06

 - 

14.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.80
Open
5.77
Volume
767,414
3M AVG Volume
20.51
Today's High
5.80
Today's Low
5.57
52 Week High
14.88
52 Week Low
5.06
Shares Out (MIL)
69.40
Market Cap (MIL)
387.97
Forward P/E
-6.03
Dividend (Yield %)
--

Next Event

Q3 2019 Fluidigm Corp Earnings Release

Latest Developments

More

Fluidigm Files Patent Infringement Suit Against IONpath

Fluidigm And The Icahn School Of Medicine At Mount Sinai Collaborate On Landmark Single-Cell Study Of The Human Epigenome

Fluidigm Reports Qtrly Loss Per Share $0.20

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Industry

Scientific & Technical Instr.

Contact Info

7000 Shoreline Ct Ste 100

+1.650.2666000

https://www.fluidigm.com/

Executive Leadership

Samuel D. Colella

Independent Chairman of the Board

Stephen Christopher Linthwaite

President, Chief Executive Officer, Director

Vikram Jog

Chief Financial Officer, Principal Accounting Officer

Nicholas S. Khadder

Senior Vice President, General Counsel, Corporate Secretary

Bradley Allen Kreger

Senior Vice President, Global Operations

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-2.620

2017

-1.840

2018

-1.490

2019(E)

-0.984
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.24
Price To Book (MRQ)
2.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
28.87
LT Debt To Equity (MRQ)
28.87
Return on Investment (TTM)
-29.32
Return on Equity (TTM)
-25.32

Latest News

BRIEF-Fluidigm Corp Q1 Revenue $25.2 Million

* FLUIDIGM ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL PROGRESS

BRIEF-Fluidigm Announces Exchange Of Convertible Notes

* FLUIDIGM - ENTERED SEPARATE TRANSACTIONS TO EXCHANGE ABOUT $125.0 MILLION OF ITS 2.75% NOTES DUE 2034 FOR ABOUT $125.0 MILLION OF NEW 2.75% NOTES DUE 2034

BRIEF-Fluidigm Announces Qtrly Loss Per Share $0.27

* FLUIDIGM ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

BRIEF-Fluidigm posts Q3 adj. loss per share $0.25​

* Fluidigm announces third quarter financial results and operational progress

BRIEF-Fluidigm enters into distribution agreement with University Of Zurich

* Fluidigm Corp - Entered into a distribution agreement with University Of Zurich to offer histocat software for multiparameter tissue analysis Source text for Eikon: Further company coverage:

BRIEF-Neuberger Berman Group LLC reports 13.65 percent passive stake in Fluidigm

* Neuberger Berman Group LLC reports a 13.65 percent passive stake in Fluidigm Corp as of August 31, 2017 - sec filing Source text : [ID:http://bit.ly/2eL1ifW] Further company coverage:

BRIEF-Fluidigm enters into licensing agreement with Baylor Genetics

* Fluidigm Corp - co, Baylor Genetics announced they have entered into a licensing agreement

BRIEF-Fluidigm announces sale of $30 mln of common stock in at-the-market equity offering

* Fluidigm announces sale of $30 million of common stock in at-the-market equity offering

BRIEF-Fluidigm posts Q2 loss per share $0.58

* Fluidigm announces second quarter financial results and operational progress

BRIEF-Fluidigm Corp announces termination of tax benefit preservation plan

* Fluidigm corporation announces termination of tax benefit preservation plan

BRIEF-Fluidigm, Ascendas Genomics announce strategic partnership

* Fluidigm and Ascendas Genomics announce strategic partnership to develop microfluidic molecular diagnostics in China

BRIEF-Fluidigm Q1 loss per share $0.59

* Fluidigm Corp says Q2 GAAP operating expenses are projected to be in range of $28 million to $29 million

BRIEF-Fluidigm Corp files for mixed shelf of upto $125 million

* Files for mixed shelf of upto $125 million -SEC filing Source text for Eikon: Further company coverage:

BRIEF-Fluidigm's board adopts a tax benefit preservation plan

* Says its board of directors has adopted a tax benefit preservation plan

BRIEF-Fluidigm names S. Christopher Linthwaite as new chief executive officer

* Fluidigm names S. Christopher Linthwaite as new chief executive officer

BRIEF-Levin Capital Strategies reports 25.2 pct passive stake in Fluidigm

* Reports 25.2 Pct Passive Stake In Fluidigm Corp As of oct 13 - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up